AstraZeneca showcases expanding cancer portfolio at major ESMO conference
At the European Society for Medical Oncology meeting in Madrid, AstraZeneca highlighted a broad range of cancer therapies, including new drug combinations and a potential next-generation targeted chemotherapy.
The ESMO congress featured twelve presidential-session presentations, four of which spotlighted AstraZeneca medicines. The company used the platform to demonstrate the breadth of its oncology pipeline, emphasizing innovative pairings of existing drugs and unveiling data on a forthcoming targeted chemotherapy candidate. Susan Galbraith, who leads AstraZeneca’s cancer research, said the session underscored both the depth of the portfolio and the quality of the new data presented.
Why it matters
The showcase signals AstraZeneca's growing influence in cancer treatment and potential new options for patients.
How this story developed
- Oct 22 Moderna and Merck shares tumble after unverified vaccine details surface on X
- Oct 23 Shares of Moderna and Merck fell sharply after unverified vaccine details were posted on X.
- Oct 24 Results are slated for presentation at the ESMO conference and have been approved for publication in NEJM.
In this story
Related stories
4 in this thread